Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose IL2 in Relapsing Remitting Multiple Sclerosis
NCT02424396Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2016
- Primary completion
- Oct 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing IL2 with Placebo (2 arms). Primary endpoint: Treg response to low dose IL2 induction course period at Day 5. Started Jun 2016; status: completed.
02
Drugs
aldesleukin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02424396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02424396.